Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
PRCT Stock Chart & Stats
$32.97
-$0.85(-0.97%)
At close: 4:00 PM EST
$32.97
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$32.11 - $103.81
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.03M
Market Cap
$1.89B
Enterprise Value$2.97B
Total Cash (Recent Filing)$302.72M
Total Debt (Recent Filing)$79.37M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 04, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding55,635,940
10 Day Avg. Volume1,088,788
30 Day Avg. Volume1,034,889
Financial Highlights & Ratios
PEG Ratio2.10
Price to Book (P/B)10.43
Price to Sales (P/S)18.70
P/FCF Ratio-40.50
Enterprise Value/Market Cap1.57
Enterprise Value/Revenue10.80
Enterprise Value/Gross Profit16.83
Enterprise Value/Ebitda-36.68
Forecast
1Y Price Target
$62.14Price Target Upside88.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial PerformancePRCT reported 2Q revenue of $79.2M, up 48% from last year and in line with the preannounced figure the company shared in July.
LeadershipLarry Wood, an industry veteran, is appointed as the new CEO of Procept Biorobotics Corp, bringing valuable perspective and expertise.
Product And Market ExpansionAll indications are positive for near- and long-term growth in a market only 15% penetrated with TAM expansion execution ongoing.
Bears Say
Leadership TransitionThe newly announced CCO transition on top of a CEO transition will create concerns about the business.
Sales GuidanceThe updated guidance came in potentially softer than expected, with raised FY25 sales guidance implying reduced sales compared to consensus.
UtilizationUtilization needs to improve, as physicians are only averaging ~1-2 procedures per month, which needs to increase to drive sustained handpiece growth.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $32.11 and its highest was $103.81 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $1.89B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Nov 04, 2025 which is in 16 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Aug 06, 2025. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.415 by $0.065.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -0.41.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 55,635,940 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.415. Following the earnings report the stock price went down -13.351%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in PRCT
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$62.14 (88.47% Upside)
$62.14 (88.47% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 199.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $785.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.27%
12-Months-Change
Fundamentals
Return on Equity
-26.40%
Trailing 12-Months
Asset Growth
37.05%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in revenue growth, both domestically and internationally, and improvements in gross margins and tariff conditions. The company has increased its financial guidance for the year and received a positive update on Medicare reimbursement. However, there are concerns over leadership changes and financial metrics like net loss and adjusted EBITDA, although these are improving. Overall, the positive aspects outweigh the challenges.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$62.14
▲(88.47% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.06% Insiders
39.03% Mutual Funds
0.14% Other Institutional Investors
42.56% Public Companies and Individual Investors